18 May 2016
EMA/CAT/379547/2016
Procedure Management and Committees Support Division

Committee for Advanced Therapies (CAT)

Minutes for the meeting on 20-21 April 2016

Chair: Paula Salmikangas - Vice-chair: Martina Schüßler-Lenz

20 April 2016, 14:00 – 18:30, room 03-E
21 April 2016, 09:00 – 18:30, room 03-E

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in the minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, the minutes are a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

In accordance with the Agency's policy on handling of declarations of interests of scientific committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced that no restriction in the involvement of meeting participants in upcoming discussions was identified.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 22 or more members were present in the room). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

CAT noted the resignation of Nicolas Ferry (France) as CAT member. CAT thanked Nicolas Ferry for his enormous contributions to the work of the CAT over the last years and wished him success with his future activities.

1.2. Adoption of agenda

The CAT agenda for 20 - 21 April 2016 was adopted with one addition: Re-adoption of the CAT meeting dates for 2016 (agenda point 7.1.2).

1.3. Adoption of the minutes

The CAT minutes of 22 - 23 March 2016 was adopted with one amendment to section 5.2.6.

2. Evaluation of ATMPs

2.1. Opinions

No items

2.2. Oral explanations

No items

2.3. Day 180 List of outstanding issues

No items

2.4. Day 120 Lists of questions

No items

2.5. Day 80 assessment reports

No items

2.6. Ongoing initial full application

No items

2.7. New applications

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

2.8. Withdrawal of initial marketing authorisation application

No items

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation no. 726/2004

No items

2.10. GMP and GCP inspections requests

No items

2.11. Type II variations

No items

2.12. Other post-authorisation activities

No items

3. Certification of ATMPs

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Opinions

3.2. Day 60 evaluation reports

No items

3.3. Ongoing initial application

No items

3.4. New applications

No items

4. Scientific Recommendation on Classification of ATMPs

4.1. New requests – appointment of CAT Co-ordinators

4.1.1. DNA plasmid vector pGX1802

Intended for the treatment of chronic hepatitis B virus infection

Scope: appointment of CAT Co-ordinator and adoption of

Action: for adoption

Document:
Request received 4 April 2016

Nominations were received. The CAT member was appointed as the CAT coordinator for this procedure.

4.1.2. Adeno-associated viral vector containing the ChrimsonR-td tomato gene

Intended for the treatment of retinitis pigmentosa

Scope: appointment of CAT Co-ordinator and adoption of timetable

Action: for adoption

Document:
Request received

Nominations were received. The CAT member was appointed as the CAT coordinator for this procedure.

4.1.3. Autologous regulatory T lymphocytes $CD3^+CD4^+CD25^+CD127^-FoxP3^+$

Intended for the treatment of, and prevention of progression of, recently diagnosed paediatric type I diabetes mellitus

Scope: appointment of CAT Co-ordinator and adoption of timetable

Action: for adoption

Document:
Request received

Nominations were received. The CAT member was appointed as the CAT coordinator for this procedure.

4.1.4. Allogeneic Epstein-Barr virus cytotoxic T lymphocytes

Intended for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder

Scope: appointment of CAT Co-ordinator and adoption of timetable

Action: for adoption

Document:

Request received

Nominations were received. The CAT member was appointed as the CAT coordinator for this procedure.

4.2. Day 30 Co-ordinators' first reports

4.2.1. Allogeneic bone marrow derived mesenchymal cells expanded *ex vivo* in synthetic media

Intended for the treatment of acute graft-versus-host disease grades III and IV resistant to first line treatment

Action: for adoption

Document:
ATMP classification report

CAT discussed the ATMP classification report. CAT adopted by consensus the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments
The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.2. Concentrate of autologous bone marrow-derived mononuclear cells

Intended for the improvement of heart function (left ventricular ejection fraction) and quality of life in patients with ischaemic post-acute myocardial infarction and in chronic heart disease

Action: for adoption

Document:
ATMP classification report

CAT discussed the ATMP classification report. CAT adopted by consensus the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments
The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.3. Live-attenuated, double-deleted *Listeria monocytogenes* (*Lm*) expressing human mesothelin

Intended for the treatment of non-small cell lung cancer

Action: for adoption

Document:
ATMP classification report

CAT discussed the ATMP classification report. CAT adopted by consensus the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments
The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.4. Live-attenuated, double-deleted *Listeria monocytogenes (Lm)* expressing prostate antigens

Intended for the treatment of prostate cancer

Action: for adoption

Document:
ATMP classification report

CAT discussed the ATMP classification report. CAT adopted by consensus the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments
The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.5. Autologous cultured fibroblasts

Intended for the indications of:
-Facial skin regeneration;
-Reducing facial wrinkles;
-Treatment of deep lines in the skin;
-Tissue loss and to heal chronic non-closing injuries;
-Treatment of acne scars

Action: for adoption

Document:
ATMP classification report

CAT discussed the ATMP classification report. CAT adopted by consensus the ATMP classification report. The classification outcome is restricted to the last two indications (tissue loss and to heal chronic non-closing injuries; treatment of acne scars). For the other claims, CAT considered that these were not therapeutic indications and the company is advised to consult the relevant national authority for the classification of their product for those uses. CAT secretariat to send the draft scientific recommendation to the European Commission for comments
The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.6. Extracellular matrix from adipose tissue

Intended for the treatment of non-healing wounds

Action: for adoption

Document:
ATMP classification report

CAT discussed the ATMP classification report. CAT adopted by consensus the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments
The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.7. Adipose derived mesenchymal stem cells

Intended for the treatment of non-healing wounds

Action: for adoption

Document:
ATMP classification report

CAT discussed the ATMP classification report. CAT adopted by consensus the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments
The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.8. Bone marrow derived mesenchymal stem cells

Intended for the treatment of children's encephalopathy, children's epilepsy, children's spinal cord injury

Action: for adoption

Document:
ATMP classification report

CAT discussed the draft classification report. CAT decided to request some additional information from the applicant before concluding on this classification request.

There was a general discussion on the criteria to differentiate between somatic cell therapy medicinal products (sCTMP) and tissue engineered products (TEP). The current position (included in the ATMP classification reflection paper[1]) is that products that induce regeneration via the secretion of paracrine factors are considered TEPs. It was acknowledged that as a consequence many cell-based ATMPs will be classified as TEPs, especially as the mechanism of action of the cell-based ATMP is not always well established in the early stages of product development. CAT decided to maintain this position but to reflect on these criteria at a later stage.

4.2.9. Autologous cultured chondrocytes

Intended for the treatment of filling of cartilage loss in knee-joint

Action: for adoption

Document:
ATMP classification report

CAT discussed the ATMP classification report.
CAT adopted by consensus the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments
The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.10. Autologous cultured fibroblasts

Intended for the treatment of superficial and deep wounds.

Action: for adoption

Document:
ATMP classification report

Further to clarification received from the applicant, the indication for this product has been updated as 'treatment of superficial and deep wounds'.

CAT discussed the ATMP classification report. CAT adopted by consensus the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments
The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

[1] See : http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/06/WC500187744.pdf

4.2.11. Autologous cultured keratinocytes

Intended for the treatment of non-healing wounds, burns, trophic ulcers

Action: for adoption

Document:
ATMP classification report

CAT discussed the ATMP classification report.
CAT adopted by consensus the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments
The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.12. Autologous cultured myoblasts

Intended for the treatment of faecal and urinary incontinence and of skeletal muscle injury

Action: for adoption

Document:
ATMP classification report

CAT discussed the ATMP classification report. CAT adopted by consensus the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments
The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.13. Autologous cultured melanocytes

Intended for the treatment of vitiligo

Action: for adoption

Document:
ATMP classification report

CAT discussed the ATMP classification report.
CAT adopted by consensus the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments
The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.3. Day 60 Co-ordinators' revised reports following List of Questions

4.3.1. Hematopoietic stem and progenitor cells (HSPC) genetically modified with zinc finger nucleases (ZFNs) to disrupt the erythroid enhancer (ENH) of the gene encoding the human transcription factor BCL11A

Intended for the treatment of β-thalassemia

Action: for adoption

Documents:
Revised ATMP classification report
Applicant's responses to LoQ dated 06.04.16.

The additional information received from the applicant was discussed . CAT adopted by majority the ATMP classification report (23 members voted in favour, 3 members and Norway disagreed with the majority view). .

A divergent position was signed by four CAT members (Belaïd Sekkali, Paolo Gasparini, Christiane Niederlaender and Marit Hystad).

The classification report was adopted and the divergent position will be attached. The final report will be sent to the applicant.

4.4. Finalisation of procedures

4.4.1. Autologous *ex vivo* expanded polyclonal $CD4^{+}CD25^{+}CD127^{lo/-}FOXP3^{+}$ regulatory T cells

Intended for the treatment of type 1 diabetes mellitus

Action: for information

Document:
ATMP classification report

Note: the European Commission raised no comments

The information was noted.

4.4.2. Deoxyribonucleic acid plasmid encoding a recombinant fusion protein consisting of the extracellular domain of human tumour necrosis factor alpha p55 receptor linked to the human immunoglobulin G1 Fc domain

Intended for the treatment of refractory chronic non-infectious uveitis

Action: for information

Document:
ATMP classification report

Note: the European Commission raised no comments

The information was noted.

4.4.3. Autologous stromal vascular fraction

Intended as an autologous lipofiller

Action: for information

Document:
ATMP classification report

Note: the European Commission raised no comments

The information was noted.

4.4.4. Autologous human bone marrow mononuclear cells

Intended for the treatment type 2 diabetes mellitus

Action: for information

Document:
ATMP classification report

Note: the European Commission raised no comments

The information was noted.

4.4.5. Autologous adipose-derived regenerative cells encapsulated in carboxymethylcellulose

Intended for cosmetic dermal filling

Action: for information

Document:
ATMP classification report

Note: the European Commission raised no comments

The information was noted.

4.5. Follow-ups and guidance

No items

5. Scientific Advice

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New requests – appointment of CAT Co-ordinators

5.2. CAT Rapporteurs' reports

5.3. Lists of issues

5.4. Finalisation of Scientific Advice procedures

5.5. Follow-up of Scientific Advice procedures

6. Pre-Pre-Authorisation Activities

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric investigation plans

No items

6.2. ITF briefing meetings in the field of ATMPs

6.3. Priority Medicines (PRIME) – Eligibility requests

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. Strategic Review & Learning meeting

CAT-PDCO-CTFG joint Strategic Review & Learning meeting will take place in Utrecht, Netherlands on 1st-2nd June 2016 under the auspices of the Dutch Presidency of the Council of the European Union

CAT resources: Hans Ovelgönne

Scope: discussion to agree on topics for the agenda. The scientific focus will be on dose finding in the context of extrapolation to children

Action: for discussion

Document**:**
Draft agenda (CAT only session)

Note**:** CAT members are asked to send proposals for agenda topics

CAT proposed topics for the CAT-only session (GMO and ATMPs; Platform technologies; New clinical trial approaches for ATMPs; Genome editing: are the current GTMP definition and the current guidelines suitable for this novel type of products). For the CAT-CTFG session, it was proposed to have some discussion on the Guideline on Investigational ATMPs.

7.1.2. New CAT plenaries dates and times

EMA resources: Patrick Celis

Scope: Change in meeting times (from current timing of Thurs 09.00 – Fri 15.00 to new timing of Weds 14.00 - Fri 12.00, to accommodate CAT workload and needs). The plenary meeting can finish on Thursday evening depending on the milestone documents for discussion and adoption.

Action: for adoption

Document:
-CAT plenary dates from April to December 2016

Note: at its plenaries in February and March 2016 the CAT discussed the new times and the rationale behind the changes.

The revised dates for 2016 were adopted.

7.2. Coordination with EMA Scientific Committees

7.2.1. Committee for Medicinal Products for Human Use (CHMP)

Scope: Summary of Outcomes (SoO) for the March 2016 meeting

Action: for information

Documents:
-Summary of Outcomes

7.2.2. Scientific Co-ordination Board (SciCoBo) - meeting 18th March 2016

CAT resources: Paula Salmikangas

Action: for information
Paula Salmikangas provided a short feedback from the discussions that took place in the SciCoBo meeting of 18 March 2016**.**

7.2.3. Benefit-risk assessment of the CHMP assessment report template

Scope: Revision of section 5, benefit-risk assessment template and guidance revision: second draft

Action: for information

Note: the CHMP adopted the template in February 2016

The information was noted.

7.2.4. Letter from the European Commission on a definition for 'principal molecular structural features'

Letter from the European Commission, requesting that a definition for 'principal molecular structural features' as referred to in Art 3(3)c of Reg (EC) No 847/2000 on similar active substance is developed by end of March 2016

Action: For information

Document:
CHMP-CAT joint document containing a proposal for principal molecular structural features for chemical, biologicals and ATMPs.

Note: during its March 2016 meetings, CAT and CHMP adopted the proposal which has been sent to the European Commission.

CAT noted the final proposal from CHMP and CAT.

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

7.3.1. Guideline on Efficacy and Safety follow up - RMP

Scope: presentation on the action plan for revision

Action: for discussion

The Action plan for the revision of the guideline on efficacy and safety follow-up – RMP for ATMPs was presented. CAT agreed with the proposal. CAT was asked to nominate a CAT member with clinical expertise to join the drafting group: nominations should be sent to CAT secretariat by 10 May 2016.

Boráň Tomáš has been appointed as CAT member replacing Nicolas Ferry.

7.3.2. Questions and Answers on minimally manipulated ATMPs

CAT drafting group: Metoda Lipnik Stangelj, Paula Salmikangas, Tiina Palomäki, Egbert Flory, Margarida Menezes Ferreira, Pieter Doevendans, Mikuláš Hrubiško

Scope: creation of a Q&A document following the discussion that took place at the CAT-CHMP joint Strategic Review & Learning meeting in May 2015

Second drafting group meeting to take place on Wednesday 20th April 2016, from 18:30hrs to 20:00hrs, room 03-G

Action: feedback from drafting group meeting

Document:
First draft of Q&A document

Note:
First meeting took place on 21st January 2016

The Questions-and-Answers document will describe the quality, non-clinical and clinical requirements for marketing authorisation for a minimally manipulated ATMP (CD34+ cells for cardiac repair). In the answers, a practical explanation will be provided on how to use the risk based approach to identify and justify deviations for the standard requirements for cell-based ATMPs as included in Annex I Part IV of Dir. 2001/83/EC.

The first draft of the Q&A document will be presented to CAT during their June 2016 meeting.

7.3.3. Development support scheme for PRIority MEdicines (PRIME)

Scope: procedure for the review of requests for PRIME eligibility for ATMPs in view of the first group of requests received by EMA with adoption of eligibility in May 2016

Action: for information

The procedure to review the eligibility requests for PRIME was presented and the role of CAT in PRIME requests for ATMPs was agreed or endorsed. It was proposed to nominate a CAT member ('CAT sponsor') for each new ATMP PRIME eligibility request at the time of submission. The CAT sponsor will be able to access the application from the start of the procedure and review the draft PRIME eligibility report which will be accessible at the time of discussion at the Oversight group (~Day 25, week before the SAWP). The CAT sponsor will present the conclusion and his/her comments on the recommendation from the SAWP during the next plenary CAT meeting. The CAT sponsor will consider especially the feasibility of the product. The CAT consideration will be included in the minutes of the plenary meeting (no separate document to be created).

7.4. Co-operation within the EU regulatory network

7.4.1. GMO assessment of authorised ATMP used in a clinical trial

Action: for information

CAT discussed if a formal ERA assessment with the involvement of the national environmental authorities is needed when an authorised ATMP will be used in a clinical trial (e.g. to investigate the combination with another medicine). Different views were expressed. There could be situations where the shedding profile could be different, e.g. in a different indication or route of administration. It was agreed that there is a need to discuss this further and to clarify the procedure, the environmental authorities need to be involved.

7.5. Co-operation with international regulators

7.5.1. ATMP cluster teleconference with FDA, Health Canada and PMDA (Japan)

The teleconference will take place during the plenary meeting on Thursday 21st April from 14.00hrs – 15.00hrs

CAT resources: Paula Salmikangas

Action: for adoption

Document table:

Agenda

The agenda was adopted

7.5.2. International Pharmaceutical Regulators Forum (IPRF) Gene therapy group

CAT resource: Paula Salmikangas

Scope: oral feedback from the teleconference that took place on 7th January and 9th March 2016

Action: for information

Documents:
Agenda
Minutes

Topic postponed to the next CAT meeting

7.6. CAT Work Plan

7.6.1. CAT assessor training (23-24 June 2016)

Moderators: Quality session: Margarida Menezes-Ferreira and Ilona Reischl; Clinical session: Martina Schüßler-Lenz and Simona Badoi; Non-clinical session: Björn Carlsson and Egbert Flory

Action: for discussion

Document:
Preliminary programme

Note: EMA will reimburse one participant per member state. Also, the training will be streamed via Webinar

Due to organisational reasons, CAT decided to postpone the CAT assessor training. A new date will be agreed and communicated as soon as identified.

7.7. Planning and reporting

7.7.1. Planning estimates of forthcoming Advanced Therapies Medicinal Products (ATMP) MAAs

Action: for information

CAT noted the information provided.

7.8. Others

No items

8. Any other business

8.1. Webinar - Advanced therapies in veterinary medicines: 25 – 27 April 2016

Scope: organised by AEMPS (Spain). Deadline for registration: 22th April 2016

Action: for information

Note: click here for full information

CAT noted the information

8.2. EMA workshop on Single Arm Trials - 30 June 2016

Scope:

Action: for information

Document: agenda

CAT noted the information

8.3. Procedure Management Department: update

Action: for information

CAT noted the information.

Date of next CAT meeting:
Wednesday 18th to Friday 20th May 2016

9. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Abbreviations / Acronyms

AR: Assessment Report

ATMP: Advanced Therapy Medicinal Product

BWP: Biologics Working Party

CAT: Committee for Advanced Therapies

CHMP: Committee for Medicinal Product for Human Use

COMP: Committee for Orphan Medicinal Products

CTFG: Clinical Trial Facilitation Group

DG: Drafting Group

EC: European Commission

ERA: Environmental Risk Assessment

FDA: Food and Drug Administration

FL: Final Letter

GCP: Good Clinical Practice

GLP: Good Laboratory Practice

GMO: Environmental Risk Assessment

GMP: Good Manufacturing Practice

HTA: Health Technology Assessment Bodies

HSPC: Hematopoietic Stem and Progenitor Cells

ITF: Innovative Task Force

JR: Joint Report

LoOI: List of outstanding issues

LoQ: List of questions

MA: Marketing Authorisation

MAA: Marketing Authorisation Applicant

MAH: Marketing Authorisation Holder

MSC: Mesenchymal stem cells

PDCO: Paediatric Committee

PMDA: Pharmaceuticals and Medical Devices Agency (Japan)

PIP: Paediatric Investigation Plan

PL: Package leaflet

PRAC: Pharmacovigilance and Risk Assessment Committee #

PRIME: Priority Medicines

RMP: Risk Management Plan

RP: Reflection paper

RSI: Request for supplementary information

SA: Scientific Advice

SAG-O: Scientific Advisory Group Oncology

SAWP: Scientific Advice Working Party

SR: Summary Report

SWP: Scientific Working Party

SME: Small and medium size enterprises

SmPC: Summary of Products Characteristics

TT: Timetable

Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists any ATMP related inspection requests (*section 2.9*) and Post-authorisation activities (*section 2.10*).

New applications (sections 2.1. to 2.12.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found here.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.3) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures**). Section 2.7 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.6.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

Withdrawal of applications (section 2.7.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

New applications (section 2.9.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

GMP and GCP Inspections Issues (section 2.10.)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Post-authorisation activities (section 2.12.)

This section lists type II variations, extension application according to Annex I of Reg. 1234/2008, re-examination procedures for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP and other issues concerning authorised medicines that are not covered elsewhere in the agenda such as annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found here.

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found here.

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found here.

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found here.

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

List of participants

including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 20-21 April 2016 meeting.

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Paula Salmikangas	Chair	Finland	No interests declared	
Ilona Reischl	Member	Austria	No interests declared	
Belaïd Sekkali	Alternate	Belgium	No interests declared	
Rozalina Kulaksazova	Member	Bulgaria	No interests declared	
Mirna Golemovic	Member	Croatia	No interests declared	
Tomáš Boráň	Member	Czech Republic	No interests declared	
Nanna Aaby Kruse	Member	Denmark	No restrictions applicable to this meeting	
Toivo Maimets	Member	Estonia	No interests declared	
Tiina Palomäki	Member	Finland	No interests declared	
Olli Tenhunen	Alternate	Finland	No interests declared	
Violaine Closson	Alternate	France	No interests declared	
Martina Schüssler-Lenz	Member (Vice-Chair)	Germany	No interests declared	
Egbert Flory	Alternate	Germany	No interests declared	
Krisztian Fodor	Member	Hungary	No interests declared	
Maura O'Donovan	Member	Ireland	No interests declared	
Paolo Gasparini	Member	Italy	No interests declared	
Una Riekstina	Member	Latvia	No interests declared	
Romaldas Mačiulaitis	Member (CHMP member)	Lithuania	No restrictions applicable to this meeting	
Guy Berchem	Alternate (to CHMP representative)	Luxembourg	No restrictions applicable to this meeting	
John J. Borg	Member (CHMP member)	Malta	No interests declared	
Johannes Hendrikus Ovelgönne	Member	Netherlands	No interests declared	
Marit Hystad	Member	Norway	No interests declared	
Rune Kjeken	Alternate	Norway	No restrictions applicable to this meeting	
Dariusz Śladowski	Member	Poland	No restrictions applicable to this meeting	
Margarida Menezes-Ferreira	Alternate (to CHMP representative)	Portugal	No interests declared	
Simona Badoi	Member	Romania	No interests declared	
Mikuláš Hrubiško	Member	Slovakia	No restrictions applicable to this meeting	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Metoda Lipnik-Stangelj	Member	Slovenia	No interests declared	
Marcos Timón	Alternate (to CHMP representative)	Spain	No interests declared	
Lennart Åkerblom	Member	Sweden	No interests declared	
Björn Carlsson	Alternate	Sweden	No interests declared	
Christiane Niederlaender	Member	United Kingdom	No interests declared	
James McBlane	Alternate	United Kingdom	No interests declared	
Pieter Doevendans	Member	Healthcare Professionals' Representative	No interests declared	
Esteve Trias-Adroher	Alternate	Healthcare Professionals' Representative	No interests declared	
Bernd Gänsbacher	Member	Healthcare Professionals' Representative	No interests declared	
Michelino Lipucci di Paola	Member	Patients' Representative	No restrictions applicable to this meeting	
Mariëtte Driessens	Alternate	Patients' Representative	No restrictions applicable to this meeting	
Ralf Sanzenbacher	Expert – via telephone*	Germany	No restrictions applicable to this meeting	
Nuria Prieto	Expert – via telephone*	Spain	No interests declared	
Riaz Zuhrie	Expert – via telephone*	UK	No interests declared	
A representative from the European Commission attended the meeting				
Meeting run with support from relevant EMA staff				

* Experts were only evaluated against the agenda topics or activities they participated in.